THE DEAL, AT A GLANCE
From the announcementBrightinsight
01What it doesThe new capital is framed around Build BrightInsight AI biomarker analytics and expand to rare disease monitoring.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Sapphire VenturesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedBrightinsight raised $80M Series CFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersBrightinsight is using its $80M Series C to extend an AI digital biomarker and therapeutic platform into biomarker analytics and rare disease monitoring for pharma…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Brightinsight · Financing Record
Explore source-linked visual explanations for Brightinsight. Unsupported claims are withheld while source review continues.
Record 1613 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →